HMHéctor Ricardo Morbidoni

Héctor Ricardo Morbidoni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Héctor Ricardo Morbidoni has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Exploring the Antimycobacterial Profile of N-Alkyl Imidazoles

    by Alejandro I. Recio-Balsells, Gabriel Di Gresia, Marcelo Luciano Merli, Julia Alejandra Cricco, Hector R. Morbidoni, Guillermo R Labadie

    The emergence of drug-resistant Mycobacterium tuberculosis strains and non-tuberculous mycobacteria (NTM) species such as Mycobacterium abscessus, highlights the urgent need for new chemotypes with broad-spectrum antimycobacterial activity. In this study,...

  • Open Access

    Bioinformatic Analysis of a Set of 14 Temperate Bacteriophages Isolated from Staphylococcus aureus Strains Highlights Their Massive Genetic Diversity

    by Cristian A. Suárez, Soledad T. Carrasco, Facundo N. A. Brandolisio, Virginia Abatangelo, Carina A. Boncompain, Natalia Peresutti-Bacci, Héctor R. Morbidoni

    To the best of our knowledge, this set of sequenced bacteriophages is the largest one in South America. Our report describes for the first time the utilization of MultiTwin software to analyze the relationship between phage protein families.


  • Open Access

    Unveiling the Biosynthetic Pathway for Short Mycolic Acids in Nontuberculous Mycobacteria: Mycobacterium smegmatis MSMEG_4301 and Its Ortholog Mycobacterium abscessus MAB_1915 Are Essential for the Synthesis of α′-Mycolic Acids

    by Cecilia B. Di Capua, Juan M. Belardinelli, Hugo A. Carignano, María V. Buchieri, Cristian A. Suarez, Héctor R. Morbidoni

    Mycobacterium abscessus is a nontuberculous mycobacterium responsible for an increasing number of hard-to-treat infections due to the impervious nature of its cell envelope, a natural barrier to several antibiotics. Mycolic acids are key components of that envelope; thus, their synthesis is a valuable target for drug development.


  • Open Access

    Phenotypic and molecular characterization of Staphylococcus aureus isolates conducted in nares of psoriatic patients attending a public hospital in Argentina

    by Carina A. Boncompain, Cristian A. Suárez, Mario Squeff, Valeria Belluzo, Gustavo Piccirilli, Ana Molteni, Ramón A. Fernández Bussy, Héctor R. Morbidoni


  • Open Access

    Evaluation of factors influencing expression and extraction of recombinant bacteriophage endolysins in Escherichia coli

    by Cecilia Lucía Balaban, Cristian Alejandro Suárez, Carina Andrea Boncompain, Natalia Peressutti-Bacci, Eduardo Augusto Ceccarelli, Héctor Ricardo Morbidoni

    Background: Endolysins are peptidoglycan hydrolases with promising use as environment-friendly antibacterials mainly when used topically. However, in general, endolysin expression is hampered by its low solubility. Thus, a critical point in endolysin industrial production is optimizing their expression, including improvement of solubility and recovery from cell extracts. Results: We report the expression of two endolysins encoded in the genome of phages infecting Staphylococcus aureus. Expression was optimized through changes in the concentration of the inducer and growth temperature during the expression. Usually, only 30–40% of the total endolysin was recovered in the soluble fraction. Co-expression of molecular chaperones (DnaK, GroEL) or N-term fusion tags endowed with increased solubility (DsbC, Trx, Sumo) failed to improve that yield substantially. Inclusion of osmolytes (NaCl, CaCl2, mannitol, glycine betaine, glycerol and trehalose) or tensioactives (Triton X-100, Tween 20, Nonidet P-40, CHAPS, N-lauroylsarcosine) in the cell disruption system (in the absence of any molecular chaperone) gave meager improvements excepted by N-lauroylsarcosine which increased recovery to 54% of the total endolysin content. Conclusion: This is the first attempt to systematically analyze methods for increasing yields of recombinant endolysins. We herein show that neither solubility tags nor molecular chaperones co-expression are effective to that end, while induction temperature, (His)6-tag location and lysis buffer additives (e.g.N-lauroylsarcosine), are sensible strategies to obtain higher levels of soluble S. aureus endolysins.


  • Exploring the chemical space of 1,2,3-triazolyl triclosan analogs for discovery of new antileishmanial chemotherapeutic agents

    by Julia Fernández de Luco, Alejandro I. Recio-Balsells, Diego G. Ghiano, Ana Bortolotti, Juán Manuel Belardinelli, Nina Liu, Pascal Hoffmann, Christian Lherbet, Peter J. Tonge, Babu Tekwani, et al.

    Triclosan and isoniazid are known antitubercular compounds that have proven to be also active against Leishmania parasites. On these grounds, a collection of 37 diverse 1,2,3-triazoles based on the antitubercular molecules triclosan and 5-octyl-2-phenoxyphenol (8PP) were designed in search of novel structures with leishmanicidal activity and prepared using different alkynes and azides. The 37 compounds were assayed against Leishmania donovani, the etiological agent of leishmaniasis, yielding some analogs with activity at micromolar concentrations and against M. tuberculosis H37Rv resulting in scarce active compounds with an MIC of 20 μM. To study the mechanism of action of these catechols, we analyzed the inhibition activity of the library on the M. tuberculosis enoyl-ACP reductase (ENR) InhA, obtaining poor inhibition of the enzyme. The cytotoxicity against Vero cells was also tested, resulting in none of the compounds being cytotoxic at concentrations of up to 20 μM. Derivative 5f could be considered a valuable starting point for future antileishmanial drug development. The validation of a putative leishmanial InhA orthologue as a therapeutic target needs to be further investigated.


  • Open Access

    Recombinant Mycobacterium bovis BCG is a promising platform to develop vaccines against Trypansoma cruzi infection

    by Iván Bontempi, Karen Leal, Estefania Prochetto, Genaro Díaz, Gabriel Cabrera, Ana Bortolotti, Hector R. Morbidoni, Sibele Borsuk, Odir Dellagostin, Iván Marcipar

    Chagas disease caused by the hemoflagelate parasite Trypanosoma cruzi is one of the most prevalent endemic parasitosis affecting 7‐8 millions of people. Due to the complexity of the infection, no vaccines are available up to now. The extraordinary adjuvant capacity of BCG was explored in this work to develop a vaccine candidate to protect against Trypanosoma cruzi infection by using recombinant BCG vaccine platform. Three antigens of the parasite corresponding to an N and a C terminal fragments of the enzyme trans‐sialidase (NT‐TS and CT‐TS respectively) and a fragment of the enzyme Cruzipain (CZf) were cloned into the vectors pUS997 and pUS2000 and transformed into the BCG Pasteur strain. In vaccinated mice, rBCG expressing NT‐TS in pUS2000 plasmid provided the highest protection and the lowest parasitemia after challenging BALB/c mice with a 50%‐lethal dose of parasites. When mice vaccinated with pUS2000‐NT‐TS were challenged with a 100%‐lethal dose of parasite, high levels of protection were also obtained, together with a low degree of cardiac lesions 120 days after infection. In immunized mice with pUS2000‐NT‐TS/rBCG clone, the proliferation of CD4+ cells from splenocytes stimulated with the TS antigen was significant; this stimulation increased IFNγ and IL‐17 within LTCD4+ cells, and IFNγ and CD107 expression within LTCD8+ cells. Therefore, pUS2000‐NT‐TS/rBCG conferred high levels of protection, which correlated with an immune response oriented towards a TH1/TH17 profile together with LTC specific response indicating that rBCG is a promising platform to develop vaccines against T. cruzi.


  • Open Access

    Weirdo19ES is a novel singleton mycobacteriophage that selects for glycolipid deficient phage-resistant M. smegmatis mutants

    by Cristian Alejandro Suarez, Jorgelina Judith Franceschelli, Sabrina Emilse Tasselli, Héctor Ricardo Morbidoni

    The sequencing and bioinformatics analysis of bacteriophages infecting mycobacteria has yielded a large amount of information on their evolution, including that on their environmental propagation on other genera such as Gordonia, closely related to Mycobacterium. However, little is known on mycobacteriophages cell biology such as the nature of their receptor(s) or their replication cycle. As part of our on-going screening for novel mycobacteriophages, we herein report the isolation and genome bioinformatics analysis of Weirdo19ES, a singleton Siphoviridae temperate mycobacteriophage with a 70.19% GC content. Nucleotide and protein sequence comparison to actinobacteriophage databases revealed that Weirdo19ES shows low homology to Gordonia phage Ruthy and mycobacteriophages falling in clusters Q and G and to singleton DS6A.Weirdo19ES also displays uncommon features such as a very short Lysin A gene (with only one enzymatic domain) and two putative HNH endonucleases. Mycobacterium smegmatis mutants resistant to Weirdo19ES are cross- resistant to I3. In agreement with that phenotype, analysis of cell envelope of those mutants showed that Weirdo19ES shares receptors with the transducing mycobacteriophage I3.This singleton mycobacteriophage adds up to the uncommonness of local mycobacteriophages previously isolated by our group and helps understanding the nature of mycobacteriophage receptors.


  • Open Access

    Mutations in the anti-sigma H factor RshA confer resistance to econazole and clotrimazole in Mycobacterium smegmatis

    by Héctor R. Morbidoni, Agustina I. de la Iglesia, Virginia Figueroa, Cecilia Di Capua, Thomas R. Ioerger, Tanya Parish

    Azole drugs such as econazole, are active on Mycobacterium tuberculosis and Mycobacterium smegmatis ; however, the identification of their target(s) is still pending. It has been reported that mutations in the non-essential system mmpL5-mmpS5 conferred resistance to econazole in M. tuberculosis . We herein report that an azole-resistant mutant screen in M. smegmatis rendered mutations in rshA, encoding a non-essential anti-sigma H protein.


  • Open Access

    Mycobacteriophage CRB2 defines a new subcluster in mycobacteriophage classification

    by Cristian Alejandro Suarez, Jorgelina Judith Franceschelli, Héctor Ricardo Morbidoni

    Mycobacteriophages are viruses -mostly temperates- that infect Mycobacterium smegmatis and sometimes Mycobacterium tuberculosis. Mycobacteriophages are grouped in clusters on the basis of the overall nucleotide sequence homology, being further divided in subclusters as more mycobacteriophage genomes are sequenced and annotated. As part of our on-going screening for novel isolates, we herein report the bioinformatics analysis of CRB2, a mycobacteriophage belonging into the Siphoviridae family that propagates at 30°C. CRB2 has a 72,217 bp genome with a 69.78% GC content that belongs to Cluster B; nucleotide comparison with other B cluster members positions CRB2 as the sole member of a new subcluster, B9, being mycobacteriophage Saguaro (belonging into subcluster B7) its closest relative. Sequencing and annotation of 14 mycobacteriophages isolated by our group has yielded six cluster A members, a singleton, four of the five members of subcluster B6, one of the three reported members of subcluster G4, and CRB2 which defines subcluster B9. Considering the massive mycobacteriophage search performed in USA and the relatively rarity of our phages, we propose that factors other than size of the sampling determine the variability of mycobacteriophage distribution, and thus a world-wide concerted mining would most likely bring extremely rare and yet undiscovered mycobacteriophages.